Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 17 |
List of Tables | 16 | 2 |
List of Figures | 18 | 1 |
Introduction | 19 | 1 |
Global Markets Direct Report Coverage | 19 | 1 |
Cervical Cancer Overview | 20 | 1 |
Therapeutics Development | 21 | 2 |
Pipeline Products for Cervical Cancer Overview | 21 | 1 |
Pipeline Products for Cervical Cancer Comparative Analysis | 22 | 1 |
Cervical Cancer Therapeutics under Development by Companies | 23 | 6 |
Cervical Cancer Therapeutics under Investigation by Universities/Institutes | 29 | 1 |
Cervical Cancer Pipeline Products Glance | 30 | 4 |
Late Stage Products | 30 | 1 |
Clinical Stage Products | 31 | 1 |
Early Stage Products | 32 | 1 |
Unknown Stage Products | 33 | 1 |
Cervical Cancer Products under Development by Companies | 34 | 7 |
Cervical Cancer Products under Investigation by Universities/Institutes | 41 | 1 |
Cervical Cancer Companies Involved in Therapeutics Development | 42 | 75 |
Abion Inc | 42 | 1 |
Admedus Ltd | 43 | 1 |
Advaxis Inc | 44 | 1 |
Advenchen Laboratories LLC | 45 | 1 |
Antigen Express Inc | 46 | 1 |
Arbor Vita Corp | 47 | 1 |
ArQule Inc | 48 | 1 |
AstraZeneca Plc | 49 | 1 |
AVEO Pharmaceuticals Inc | 50 | 1 |
Azaya Therapeutics Inc | 51 | 1 |
Bioleaders Corporation | 52 | 1 |
Biomics Biotechnologies Co Ltd | 53 | 1 |
Blirt SA | 54 | 1 |
Boehringer Ingelheim GmbH | 55 | 1 |
Bristol-Myers Squibb Company | 56 | 1 |
Cancer Research Technology Ltd | 57 | 1 |
Cell Medica Ltd | 58 | 1 |
Cellceutix Corp | 59 | 1 |
Coherus BioSciences Inc | 60 | 1 |
Critical Outcome Technologies Inc | 61 | 1 |
CZ BioMed Corp | 62 | 1 |
DelMar Pharmaceuticals, Inc. | 63 | 1 |
Dr. Reddy's Laboratories Ltd | 64 | 1 |
EirGenix Inc. | 65 | 1 |
Eisai Co Ltd | 66 | 1 |
Etubics Corp | 67 | 1 |
Eureka Therapeutics Inc | 68 | 1 |
EyeGene Inc | 69 | 1 |
F. Hoffmann-La Roche Ltd | 70 | 1 |
Formune SL | 71 | 1 |
GamaMabs Pharma SA | 72 | 1 |
Gene Techno Science Co Ltd | 73 | 1 |
Genexine Inc | 74 | 1 |
Genmab A/S | 75 | 1 |
Genor BioPharma Co Ltd | 76 | 1 |
Genticel S.A. | 77 | 1 |
GlaxoSmithKline Plc | 78 | 1 |
Immune Therapeutics, Inc. | 79 | 1 |
Immunovaccine Inc | 80 | 1 |
INSYS Therapeutics Inc | 81 | 1 |
ISA Pharmaceuticals BV | 82 | 1 |
Johnson &Johnson | 83 | 1 |
Karyopharm Therapeutics Inc | 84 | 1 |
Kite Pharma Inc | 85 | 1 |
LondonPharma Ltd | 86 | 1 |
Mabion SA | 87 | 1 |
Merck &Co Inc | 88 | 1 |
Mycenax Biotech Inc | 89 | 1 |
Nanotherapeutics Inc | 90 | 1 |
Nektar Therapeutics | 91 | 1 |
Oncobiologics Inc | 92 | 1 |
Ono Pharmaceutical Co Ltd | 93 | 1 |
Oryx GmbH &Co KG | 94 | 1 |
PDS Biotechnology Corp | 95 | 1 |
Pfizer Inc | 96 | 1 |
Psicofarma SA de CV | 97 | 1 |
Rexahn Pharmaceuticals Inc | 98 | 1 |
Richter Gedeon Nyrt | 99 | 1 |
Samyang Holdings Corp | 100 | 1 |
Sanofi | 101 | 1 |
Savoy Pharmaceuticals, Inc. | 102 | 1 |
Seattle Genetics Inc | 103 | 1 |
Selecta Biosciences Inc | 104 | 1 |
Shantha Biotechnics Ltd | 105 | 1 |
Sirnaomics Inc | 106 | 1 |
Sun Pharma Advanced Research Company Ltd | 107 | 1 |
Taiho Pharmaceutical Co Ltd | 108 | 1 |
Tessa Therapeutics Pte Ltd | 109 | 1 |
Theravectys SA | 110 | 1 |
THEVAX Genetics Vaccine USA Inc | 111 | 1 |
Tomegavax Inc | 112 | 1 |
UbiVac LLC | 113 | 1 |
VLPbio | 114 | 1 |
Zeria Pharmaceutical Co Ltd | 115 | 1 |
Zydus Cadila Healthcare Ltd | 116 | 1 |
Cervical Cancer Therapeutics Assessment | 117 | 16 |
Assessment by Monotherapy Products | 117 | 1 |
Assessment by Combination Products | 118 | 1 |
Assessment by Target | 119 | 5 |
Assessment by Mechanism of Action | 124 | 5 |
Assessment by Route of Administration | 129 | 2 |
Assessment by Molecule Type | 131 | 2 |
Drug Profiles | 133 | 318 |
(hydralazine + valproate magnesium) Drug Profile | 133 | 1 |
ABN-301 Drug Profile | 134 | 1 |
AEH-10p Drug Profile | 135 | 1 |
AL-3818 Drug Profile | 136 | 2 |
Ancer Drug Profile | 138 | 1 |
Antisense RNAi Oligonucleotide for Cervical Cancer Drug Profile | 139 | 1 |
Aptamer to Target HPV E7 Protein for Cervical Cancer Drug Profile | 140 | 1 |
ARQ-092 Drug Profile | 141 | 3 |
artemether Drug Profile | 144 | 2 |
atezolizumab Drug Profile | 146 | 14 |
AV-203 Drug Profile | 160 | 3 |
AVC-7 Drug Profile | 163 | 1 |
axalimogene filolisbac Drug Profile | 164 | 17 |
AZD-5363 Drug Profile | 181 | 3 |
bevacizumab biosimilar Drug Profile | 184 | 2 |
bevacizumab biosimilar Drug Profile | 186 | 1 |
bevacizumab biosimilar Drug Profile | 187 | 1 |
bevacizumab biosimilar Drug Profile | 188 | 1 |
bevacizumab biosimilar Drug Profile | 189 | 1 |
bevacizumab biosimilar Drug Profile | 190 | 1 |
bevacizumab biosimilar Drug Profile | 191 | 1 |
bevacizumab biosimilar Drug Profile | 192 | 1 |
bevacizumab biosimilar Drug Profile | 193 | 1 |
bevacizumab biosimilar Drug Profile | 194 | 1 |
bevacizumab biosimilar Drug Profile | 195 | 1 |
BLR-111 Drug Profile | 196 | 1 |
BLSILSB-710c Drug Profile | 197 | 1 |
BMS-986016 Drug Profile | 198 | 2 |
BVAC-C Drug Profile | 200 | 1 |
Cellular Immunotherapy for HPV Associated Cancers Drug Profile | 201 | 1 |
Cellular Immunotherapy for Oncology Drug Profile | 202 | 1 |
Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer Drug Profile | 203 | 2 |
Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer Drug Profile | 205 | 2 |
CerviVax Drug Profile | 207 | 1 |
Cervlysis Drug Profile | 208 | 1 |
CIGB-300 Drug Profile | 209 | 2 |
CMD-004 Drug Profile | 211 | 1 |
COTI-2 Drug Profile | 212 | 8 |
crocetin Drug Profile | 220 | 1 |
dianhydrogalactitol Drug Profile | 221 | 12 |
docetaxel Drug Profile | 233 | 2 |
DPXE-7 Drug Profile | 235 | 1 |
E-7046 Drug Profile | 236 | 1 |
EDA-HPVE7 Drug Profile | 237 | 1 |
EDOB-278 Drug Profile | 238 | 1 |
EF-022 Drug Profile | 239 | 1 |
EG-HPV Drug Profile | 240 | 1 |
Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer Drug Profile | 241 | 1 |
ET-1502 Drug Profile | 242 | 1 |
ETBX-041 Drug Profile | 243 | 1 |
etirinotecan pegol Drug Profile | 244 | 6 |
GM-102 Drug Profile | 250 | 2 |
GSK-2256098 Drug Profile | 252 | 2 |
GSK-2849330 Drug Profile | 254 | 1 |
GTL-001 Drug Profile | 255 | 3 |
GTL-002 Drug Profile | 258 | 1 |
GX-I7 Drug Profile | 259 | 1 |
HPViNT Drug Profile | 260 | 1 |
human papillomavirus vaccine Drug Profile | 261 | 1 |
human papillomavirus vaccine Drug Profile | 262 | 1 |
human papillomavirus vaccine Drug Profile | 263 | 1 |
human papillomavirus vaccine Drug Profile | 264 | 1 |
human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar Drug Profile | 265 | 1 |
ISA-101 Drug Profile | 266 | 3 |
JNJ-61610588 Drug Profile | 269 | 1 |
Kevetrin Drug Profile | 270 | 11 |
KITE-439 Drug Profile | 281 | 1 |
LN-145 Drug Profile | 282 | 2 |
Lovaxin S Drug Profile | 284 | 1 |
Monoclonal Antibody Conjugate to Target CD40 for Cervical, Head And Neck Cancer Drug Profile | 285 | 1 |
naltrexone hydrochloride Drug Profile | 286 | 3 |
nimotuzumab Drug Profile | 289 | 4 |
nintedanib Drug Profile | 293 | 10 |
NIT-02 Drug Profile | 303 | 1 |
nivolumab Drug Profile | 304 | 34 |
NP-001 Drug Profile | 338 | 1 |
NTO-1151 Drug Profile | 339 | 2 |
Oncoprev Drug Profile | 341 | 1 |
OTAC-DCtag Drug Profile | 342 | 1 |
paclitaxel Drug Profile | 343 | 2 |
paclitaxel Drug Profile | 345 | 4 |
paclitaxel albumin free Drug Profile | 349 | 1 |
PDS-0101 Drug Profile | 350 | 2 |
pembrolizumab Drug Profile | 352 | 38 |
PF-04518600 Drug Profile | 390 | 2 |
phosphoethanolamine Drug Profile | 392 | 1 |
RA-190 Drug Profile | 393 | 1 |
Recombinant Protein to Inhibit NFKB for Cervical Cancer and Breast Cancer Drug Profile | 394 | 1 |
RG-7876 Drug Profile | 395 | 1 |
RX-3117 Drug Profile | 396 | 5 |
S-009131 Drug Profile | 401 | 1 |
SAR-408701 Drug Profile | 402 | 1 |
SEL-701 Drug Profile | 403 | 1 |
selinexor Drug Profile | 404 | 19 |
SGN-LIV1A Drug Profile | 423 | 2 |
sirolimus albumin-bound Drug Profile | 425 | 2 |
Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology Drug Profile | 427 | 1 |
STP-900 Drug Profile | 428 | 1 |
Subunit Vaccine for HPV Associated Cervical Cancer Drug Profile | 429 | 1 |
Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology Drug Profile | 430 | 1 |
TA-CIN Drug Profile | 431 | 1 |
TAS-114 Drug Profile | 432 | 1 |
Tenacinol Drug Profile | 433 | 1 |
tisotumab vedotin Drug Profile | 434 | 2 |
TT-12 Drug Profile | 436 | 1 |
TVGV-1 Drug Profile | 437 | 1 |
utomilumab Drug Profile | 438 | 2 |
Vaccine for HPV Associated Cancers Drug Profile | 440 | 1 |
Vaccine for HPV Associated Cervical Cancer Drug Profile | 441 | 1 |
Vaccine for HPV Associated Cervical Cancer Drug Profile | 442 | 1 |
Vaccine for HPV Associated Cervical Cancer Drug Profile | 443 | 1 |
Vaccine for Human papillomavirus Associated Cervical Cancer Drug Profile | 444 | 1 |
Vaccine to Target HIG2, VEGFR-1 and VEGFR-2 for Ovarian Cancer and Cervical Cancer Drug Profile | 445 | 1 |
Vaccine to Target HPV E7 Protein for Cervical Cancer Drug Profile | 446 | 1 |
Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer Drug Profile | 447 | 1 |
Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer Drug Profile | 448 | 1 |
Vicoryx Drug Profile | 449 | 1 |
Vvax-001 Drug Profile | 450 | 1 |
Cervical Cancer Dormant Projects | 451 | 7 |
Cervical Cancer Discontinued Products | 458 | 1 |
Cervical Cancer Product Development Milestones | 459 | 12 |
Featured News &Press Releases | 459 | 1 |
Nov 11, 2016: Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting | 459 | 1 |
Oct 26, 2016: Immune Therapeutics Announces Filing Acceptance of New Drug Applications for Lodonal for the Treatment of Patients with Human Immuno-Deficiency, Cancer and as an Immune Booster | 460 | 1 |
Oct 24, 2016: Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2 | 461 | 1 |
Oct 20, 2016: Advaxis Initiates Phase 3 Study of Axalimogene Filolisbac | 462 | 1 |
Oct 19, 2016: Kite Pharma provides update on KITE-439 clinical development program at Investor Day | 462 | 1 |
Oct 05, 2016: Karyopharm to Present Updated SIGN Phase 2 Clinical Data at European Society of Medical Oncology 2016 Annual Meeting | 462 | 2 |
Sep 26, 2016: Advaxis Lm Technology Immunotherapies to be Showcased in Three Poster Presentations at SITC Annual Meeting | 464 | 1 |
Aug 23, 2016: Immune Therapeutics Through Its Wholly Owned Subsidiary TNI BioTech International Initiates Clinical Trial In Malawi With LDN For The Prevention Of Cervical Cancer | 464 | 1 |
Jul 26, 2016: Phase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort | 465 | 1 |
Jul 22, 2016: Genexine Confirms Possibility of Treatment in Cervicovaginal Tumor with Combination Therapy of hyFc-fused Interleukin-7 and HPV DNA Vaccine | 466 | 1 |
Jul 21, 2016: Advaxis AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients | 466 | 1 |
Jul 18, 2016: European Medicines Agency Committee Classifies Advaxis Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product | 467 | 1 |
Jul 06, 2016: FDA Grants Special Protocol Assessment to Advaxis Phase 3 Study of AXAL in Patients with Cervical Cancer | 468 | 1 |
Jun 06, 2016: Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports | 468 | 1 |
Jun 06, 2016: Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study | 469 | 2 |
Appendix | 471 | 2 |
Methodology | 471 | 1 |
Coverage | 471 | 1 |
Secondary Research | 471 | 1 |
Primary Research | 471 | 1 |
Expert Panel Validation | 471 | 1 |
Contact Us | 471 | 1 |
Disclaimer | 472 | 1 |